Navigation Links
Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
Date:11/8/2012

CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

The data demonstrate that women taking bremelanotide showed statistically significant increases in the number of Satisfying Sexual Events (SSEs) and also showed statistically significant improved measures of overall sexual functioning and distress related to sexual dysfunction, compared with placebo.

The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, shows a clinically meaningful and statistically significant improvement (p=0.018) in the number of SSEs in women taking bremelanotide doses (mean change from 1.6 at baseline increasing to 2.4; pooled 1.25 mg and 1.75 mg doses) versus placebo (mean change from 1.7 at baseline increasing to 1.9) over the study period, resulting in a 50% increase in SSEs with bremelanotide versus 12% with placebo.

"We are extremely pleased to report the successful completion of this trial, which achieved statistical significance in our primary endpoint and key secondary endpoints using independently developed and validated measurement tools. Importantly, we met the objectives of the trial which demonstrated excellent safety and efficacy of the drug and identified doses for advancement into Phase 3 trials and activities" stated Carl Spana, Ph.D., President and CEO of Palatin. "Our next steps are to continue to compile and analyze additional data, to start the preparation process for an end-of-Phase 2 meeting with the FDA, and to further our discussions with potential colla
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
(Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- Xybion Corporation, the leading provider of ... in highly regulated industries, announced today that the ... Group Conference, Xybion International Exchange, on October 21-23, ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance Fusion.  ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... leaders, experts and foreign ministry delegations set to be involved in ... ... Singapore (PRWEB) March 2, 2009 -- Asia-Pacific,s largest and most ... Asia 2009 (GSA 2009), will be held in Singapore from 17th ...
... LOUIS, Feb. 27 A copy of the Company,s December ... Exchange Commission, may be obtained without charge at our website ... Sigma-Aldrich Corporation, P. O. Box 14508, St. Louis, Missouri 63178. ... Life Science and High Technology ...
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... time in response to Astellas Pharma Inc.,s announcement that ... unsolicited tender offer for all outstanding common shares of ... in cash. CV Therapeutics, board of directors, in ...
Cached Biology Technology:News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 2News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 3CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 2CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 3
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... DURHAM, N.C. -- Microorganisms like bacteria and fungi can ... by antibiotics or antifungal drugs. These permanent mutations were ... strains to evolve. Now a new study has shown ... targets -- known as epimutations -- to gain the ... the new mechanism was discovered in a fungus called ...
Breaking Biology News(10 mins):Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... of evolution is periodically marked by explosions in biodiversity, ... of shapes and sizes. With a new analysis of ... have discovered that these diversifications proceeded head-first. By ... around the time of two separate extinction events, scientists ...
... are fascinating plant organs they not only anchor the ... Roots live in darkness and direct the activities of the ... Charles Darwin posited in The Power of Movement of Plants ... Due to the difficulty of accessing root tissue in ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3New tool offers unprecedented access for root studies 2
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
Purified anti-LAT...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Purified anti-human CD182 (CXCR2)...
Biology Products: